Celera Corporation
(CRA:NASDAQ)
Snapshot of Celera Corporation (CRA)
|
OPEN
$6.31
|
PREVIOUS CLOSE
$6.25
|
|
|
DAY HIGH
$6.49
|
DAY LOW
$6.20
|
|
|
52 WEEK HIGH
01/6/09 - $11.71
|
52 WEEK LOW
03/17/09 - $5.03
|
|
|
MARKET CAP
515.4M
|
AVERAGE VOLUME 3 mo
420.0K
|
|
|
DILUTED EPS TTM
--
|
SHARES OUTSTANDING
81.9M
|
|
|
CRA Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
related business week news
What Wall Street analysts are saying about selected stocks in the news Monday
CRA Details
Celera Corporation delivers personalized disease management through a combination of products and services. It operates in three segments: Lab Services, Products, and Corporate. The Lab Services segment offers clinical laboratory tests and disease management services for healthcare providers to enhance cardiovascular disease treatment regimens for patients. It offers clinical laboratory testing services that characterize and monitor cardiovascular disease risk, and personalized treatment and ongoing therapeutic compliance education services. The principal tests offered by this segment include LDL-S3GGE test that measures low-density lipoprotein (LDL) size as a subclass distribution divided in seven regions and characterizes the amount of LDL distributed in these regions; HDL-S10GGE test that measures high-density lipoprotein (HDL) size as a subclass distribution divided across five HDL regions and characterizes the amount of HDL distributed in these regions; Apolipoprotein E Genotypes test for lipoprotein metabolism; and Kinesin-Like Protein 6 test, which detects a variant in a gene called Kinesin-Like Protein 6. The Products segment develops and manufactures molecular diagnostic products for disease detection, prediction of disease predisposition, monitoring of disease progression and disease severity, and determination of patient responsiveness to treatments. It has a strategic alliance with Abbott Laboratories to discover, develop, and commercialize molecular diagnostic products for disease detection, prediction of disease predisposition, disease progression monitoring, and therapy selection. The Corporate segment licenses small molecule drug development programs and Life Technologies’ intellectual property to third parties for use in the diagnostic field; and establishes collaborations to develop cancer therapies based on its proteomics discoveries. The company was founded in 1998 and is headquartered in Alameda, California.
CRA Top Compensated Officers
Key developments for Celera Corporation (CRA)
Celera Corporation reported unaudited consolidated earnings results for the third quarter and nine months ended September 26, 2009. Net revenues of $40.0 million for the third quarter of 2009 that ended September 26, 2009, compared to $45.8 million in the prior year quarter. For the third quarter of 2009, the company reported a net loss of $7.4 million, or $0.09 per share, compared to a net loss of $7.0 million, or $0.09 per share, for the prior year quarter. Operating loss was $8.8 million against $6.3 million a year ago. Loss before tax was $7.4 million against $7.0 million a year ago. For the third quarter of 2009, these items increased the net loss by $7.1 million, and included expenses associated with the previously announced restructuring program and other charges. Amortization of purchased intangible assets, employee-related charges, asset impairments, litigation-related charge and legal settlement and non-cash interest income impacts third quarter results. For the third quarter of 2008, these items increased the net loss for the quarter by $7.6 million. Excluding the items, the company's net loss on a non-GAAP basis for the third quarter of 2009 was $0.3 million, or breakeven on a per share basis, compared to net income of $0.6 million, or $0.01 per share, for the prior year quarter. Non-GAAP loss before income taxes was $0.3 million against income of $0.6 million a year ago. For the nine months period, the company reported loss before tax of $46.8 million and net loss of $40.5 million or $0.50 per basic and diluted share on net revenue of $127.1 million against loss before tax of $23.5 million and net loss of $118.5 million or $1.48 per basic and diluted share on net revenue of $128.0 million reported a year ago. Operating loss was $52.0 million against $25.9 million a year ago. Under Non-GAAP, net loss was $18.8 million or $0.23 per diluted share against net loss of $1.3 million or $0.02 per diluted share reported a year ago. Non-GAAP loss before income taxes was $18.8 million against $2.4 million a year ago. For the fourth quarter of 2009, the company anticipates a net loss of $4-$6 million, or $0.05-$0.07, on a non-GAAP basis. For the year 2009, total revenues are anticipated to be $163-$167 million, the same mid-point as prior guidance of $160-$170 million. Gross margin, as a percentage of revenue, is anticipated to be 66-70%.
Celera Corporation, Q3 2009 Earnings Call, Oct 28 2009
Celera Corporation expected to Report Fiscal Year 2009 Results on February 15, 2010. This event was calculated by Capital IQ (Created on October 21, 2009).
Stock Quotes
| Recently Viewed | |||
| CRA | $6.29 USD | +0.04 | |
|---|---|---|---|
| BA | $52.63 USD | +0.93 | |
| NSOL | $0.03 USD | -0.001 | |
| CVS | $31.89 USD | +0.25 | |
| PRD | $13.15 USD | +0.04 | |
Market data is delayed at least 20 minutes.
CRA Competitors
| Company | Last | Change |
| ABAXIS Inc | $23.12 USD | +0.56 |
| Genomic Health Inc | $19.38 USD | +0.09 |
| Luminex Corporation | $13.91 USD | -0.01 |
| Quidel Corp | $13.21 USD | -0.02 |
| ZymoGenetics Inc | $5.84 USD | -0.08 |
| View Industry Companies | ||
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | CRA | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 3.0x |
|
| Price/Book | 0.8x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 1.1x |
|
|
CRA |
||
CRA transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
Companies Toolbox
SEARCH FOR JOBS
Post a Job- Painesville, OH-Avery Dennison
- Houston, TX-Halliburton
- Houston, TX-Halliburton
- New York, NY-Duff & Phelps
Jobs by SimplyHired
Recommend A Data Enhancement Or Correction
For Celera Corporation (CRA) Snapshot
Submitting this data update / error report instantly puts the correct information in the hands of our researcher, who will investigate your report and, if necessary, make the changes to the company profile. Be sure to fill out the form completely.
Please indicate in which section the error appears. Section headers are in light gray type at the top of each CIC page module.
Please indicate which data is in error.
Please provide your name and email address in case our researchers need to get in touch with you as they investigate the error.
Describe why you feel the data point is incorrect and indicate sources our researchers should check when they investigate the error.



